Recently, Kosaraju et al. verified the neuroprotective activity of linagliptin in a 3xTg-AD mouse model (harboring triple PS1, APP and tau mutations) with concurrent β-amyloid and tau pathology [27]. The gene discussed is MAPT; the disease is Alzheimer disease.